Hainan bans single-use non-degradable plastic products from being imported into the island
Time of Update: 2022-08-28
In order to prevent and control the illegal import of disposable non-degradable plastic products from outside the province in accordance with the law, the Hainan Provincial Department of Transportation and the Hainan Provincial Market Supervision and Administration Bureau jointly issued the "Hainan Province Prohibits the Import of Disposable Non-degradable Plastic Products from Outside the Province into the Island".
280 pharmacies have a good harvest
Time of Update: 2021-11-15
25 million yuan, involving 12 stores, and the equity transfer procedures of the project were completed in July 2021 .
79 million yuan, involving 20 stores, the project equity delivery procedures were completed in August .
It's time to eradicate Helicobacter pylori in the stomach
Time of Update: 2021-08-03
pylori, the bacteria has 2-6 flagella, it is the only bacteria that can survive the strong acid environment of the stomach, living under the gastric mucosa Between the epithelium of the gastric mucosa and the epithelium of the gastric mucosa, it can actively invade mucosal epithelial cells .
"Angel" or "devil"? Where is the much-watched Qumador Road
Time of Update: 2021-03-25
Figure 1 Sales and change trends of "analgesic family" and tramadol over the years
Subdividing the family of analgesics and selecting representative drugs for analysis (see Figure 2), we found that dezocine has suddenly risen, and sales have soared from 392 million yuan in 2012 to 2.
2020 Tumor New Drug Data Card - Atili Zhu monoanti
Time of Update: 2021-03-09
Advanced non-small cell lung cancer anti-angiogenesic drug therapy China expert consensus (2020 version) recommendation 2: In patients with advanced non-scale NSCLC who drive gene mutation negative and PS 0 to 1 points, recommended atilijutin monoantigen combined beva bead monoanti, carpentry and yew alcohol program as a first-line treatment option (II.grade recommendation, class 1A evidence).
The first CAR-T treatment for inert non-Hodgkin's lymphoma is expected to be available
Time of Update: 2020-11-16
On May 5, Gilead Sciences Inc.'s Kite Corporation announced that it has submitted to the FDA a request for a complementary biological product license (sBLA) for car-T cell therapy Yescarta (axicabtagene ciloleucel) for the treatment of patients with recurring/refractic follicle lymphoma and marginal lymphoma who have received more than two systemic treatments.